A Aralex Aachen research explorer

Company ROR OpenAlex

Galapagos (Netherlands) Sign in to save

159 stored papers · Search its papers → · Its authors →

Papers 159

AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES
2023 conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

1

citations
Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma
2023 Blood conference-abstract Medicine CAR-T cell therapy research

1

citations
Impact of Gamma-Secretase Inhibition on the Multiple Myeloma Immune Microenvironment
2023 Blood conference-abstract Medicine Multiple Myeloma Research and Treatments Open access

1

citations
P551 Benefit–risk trade-offs and patient preferences for therapy selection in Ulcerative Colitis: a multi-country preference study
2024 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

1

citations
P133 In vitro pharmacological profile of GLPG3667 suggests differentiation from the TYK2 inhibitors deucravacitinib and TAK-279 at their clinical dose regimens
2024 Journal of Crohn s and Colitis conference-abstract Medicine Cytokine Signaling Pathways and Interactions Open access

1

citations
The MANGROVE Phase 2 Trial: Study Design and Baseline Characteristics of Patients With Autosomal Dominant Polycystic Kidney Disease
2022 Journal of the American Society of Nephrology conference-abstract Biochemistry, Genetics and Molecular Biology Genetic and Kidney Cyst Diseases

1

citations
POS0051 AN UPDATE ON THE INTEGRATED SAFETY ANALYSIS OF FILGOTINIB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS OVER A MEDIAN OF 4.3 YEARS
2024 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

1

citations
THU0188 EFFICACY OF FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH POOR PROGNOSTIC FACTORS: POST HOC ANALYSIS OF FINCH 3
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

0

citations
FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

0

citations
Amélioration sous filgotinib [FIL] des symptômes (douleur, fatigue, état fonctionnel et qualité de vie) rapportés par les patients atteints de polyarthrite rhumatoïde [PR] avec une réponse inadéquate au méthotrexate (MTX-IR) : résultats de l’étude FINCH 1
2020 Revue du Rhumatisme article Medicine Rheumatoid Arthritis Research and Therapies

0

citations
Analyse intégrée de 7 essais cliniques sur la tolérance du filgotinib [FIL] dans le traitement de la polyarthrite rhumatoïde [PR]
2020 Revue du Rhumatisme article Medicine Rheumatoid Arthritis Research and Therapies

0

citations
Impact du filgotinib sur les lésions structurelles des articulations sacro-iliaques (ASI) à 12 semaines chez les patients atteints de spondylarthrite axiale (AxSpA) active : données d’Imagerie par résonance magnétique (IRM) issues de l’essai TORTUGA
2020 Revue du Rhumatisme article Medicine Spondyloarthritis Studies and Treatments

0

citations
Faible activité et rémission sous filgotinib [FIL] chez les patients PR ayant présenté une réponse inadéquate aux bDMARDs: analyse en sous-groupes de l’étude de phase 3 FINCH2
2020 Revue du Rhumatisme article Medicine Rheumatoid Arthritis Research and Therapies

0

citations
316P Implementation of Vela Analytics to accelerate comprehensive interpretation and reporting of next-generation sequencing-based oncology testing in clinical diagnostic laboratories
2020 Annals of Oncology article Biochemistry, Genetics and Molecular Biology Cancer Genomics and Diagnostics Open access

0

citations
Amélioration sous filgotinib [FIL] des symptômes (douleur, fatigue et qualité de vie) rapportés par les patients atteints de polyarthrite rhumatoïde [PR] avec une réponse inadéquate aux bDMARDs : résultats de l’étude FINCH 2
2020 Revue du Rhumatisme article Medicine Rheumatoid Arthritis Research and Therapies

0

citations
P133 Filgotinib in patients with RA with inadequate response to methotrexate: FINCH 1 52-week efficacy and patient reported outcomes data
2021 Lara D. Veeken conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access

0

citations
THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
2020 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

0

citations
POS1037 CORRELATION BETWEEN SKIN INVOLVEMENT, JOINT INVOLVEMENT AND ENTHESITIS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POST-HOC ANALYSIS OF EQUATOR/EQUATOR2
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments

0

citations
POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM
2021 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies

0

citations
OMO-2 Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results
2021 conference-paper Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access

0

citations

Most cited authors